Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

285
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
285
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

528
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
528
Fats as Energy Storage Molecules01:06

Fats as Energy Storage Molecules

26.7K
Triglycerides are a form of long-term energy storage molecules. They are made of glycerol and three fatty acids. To obtain energy from fat, triglycerides must first be broken down by hydrolysis into their two principal components, fatty acids and glycerol. This process, called lipolysis, takes place in the cytoplasm. The resulting fatty acids are oxidized by β-oxidation into acetyl-CoA, which is used by the Krebs cycle. The glycerol that is released from triglycerides after lipolysis...
26.7K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.2K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

4.6K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same author

Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk.

Pharmacology & therapeutics·2026
Same author

Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target.

Current atherosclerosis reports·2026
Same author

Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.

European heart journal·2026
Same author

Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know.

Atherosclerosis·2025
Same author

Editorial: The Brussels International Declaration on Lp(a) Testing And Management-A call to action.

Atherosclerosis·2025
Same journal

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026
Same journal

The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

European heart journal·2026
Same journal

Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

European heart journal·2026
Same journal

Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis.

European heart journal·2026
Same journal

Myths and misconceptions about high-sensitivity C-reactive protein as a marker of residual inflammatory risk.

European heart journal·2026
Same journal

Vascular Ehlers-Danlos syndrome: should we treat asymptomatic patients?

European heart journal·2026
See all related articles

Related Experiment Video

Updated: Jan 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Triglyceride lowering 2.0: back to the future?

Chris J Packard1

  • 1Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

European Heart Journal
|November 17, 2019
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K
Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads
07:59

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads

Published on: July 21, 2017

10.0K

Related Experiment Videos

Last Updated: Jan 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.6K
Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads
07:59

Measurement of Basal and Forskolin-stimulated Lipolysis in Inguinal Adipose Fat Pads

Published on: July 21, 2017

10.0K